Acquisition of Own Shares
Lakefront Biotherapeutics repurchased 125,517 of its own shares between September 7 and September 11, 2026, spending roughly €3.0 million at an average price of €23.95 per share. The purchases were executed via a discretionary mandate to an independent financial intermediary under the repurchase program announced June 9, 2026, and spanned Euronext and other European trading venues at prices between €23.20 and €24.56. As of the September 11 market close, the company held 1,418,855 of its own ordinary shares.
Key figures
- Program announced
- June 9, 2026
- Repurchase window
- 2026-09-07 to 2026-09-11
- Avg price paid eur
- 23.95
- Shares repurchased
- 125517
- Treasury shares held
- 1418855
- Lowest price paid eur
- 23.2
- Highest price paid eur
- 24.56
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.